ACCESS Newswire
25 Mar 2020, 20:49 GMT+10
LONDON, UK / ACCESSWIRE / March 25, 2020 / Silence Therapeutics (LSE:SLN) announced on 25 March 2020 that it has signed a collaboration agreement with AstraZeneca to develop novel drugs for cardiovascular, renal, metabolic and respiratory diseases. The deal includes an upfront of $60m, $20m in equity investment, and for each of the planned targets $400m in milestones, and high single- to low double-digit royalties. Additionally, the company announced that it would elevate SLN360 to the status of lead asset and expects to file an IND later in 2020 and to have interim results in mid-2021.
We have increased our valuation to £462m or 559p per basic share, from £345m or 440p per basic share. This is driven by the addition of the AstraZeneca deal metrics and its associated cash injections to our models (total £74m value uplift), an increase in the valuation of SLN360 to £167m from £112m and offset by the delay to SLN124 (£129m from £141m).
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Nathaniel Calloway, +1 646 653 7036
[email protected]
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationNEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...
ABU DHABI, 19th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has become the first and only research hospital in the UAE to receive...
ABU DHABI, 17th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion...
ABU DHABI, 9th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery...
ABU DHABI,16th May, 2025 (WAM) - Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking...
ABU DHABI, 6th May, 2025 (WAM) -- PureHealth and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati...
Argentinian composer Lalo Schifrin, the genre-blending film and television composer behind the Mission: Impossible, Bullitt, and Cool...